|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
69,704 |
$98,418,562.80 |
8.16% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
314,456 |
$92,229,944.80 |
7.64% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
303,318 |
$85,569,040.98 |
7.09% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,833,211 |
$82,814,757.53 |
6.86% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
545,701 |
$81,178,480.76 |
6.73% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,441,957 |
$50,035,698.93 |
4.15% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
186,090 |
$47,428,758.30 |
3.93% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
275,488 |
$46,645,628.16 |
3.87% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
50,461 |
$46,422,101.56 |
3.85% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
93,774 |
$43,626,478.02 |
3.62% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
522,907 |
$43,045,704.24 |
3.57% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
70,127 |
$40,846,172.42 |
3.39% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
74,037 |
$40,784,762.19 |
3.38% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
323,549 |
$39,437,387.61 |
3.27% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
603,444 |
$37,498,010.16 |
3.11% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
449,113 |
$32,219,366.62 |
2.67% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
128,185 |
$31,218,815.83 |
2.59% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
93,110 |
$20,556,825.80 |
1.70% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
27,775 |
$18,690,630.75 |
1.55% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
161,873 |
$16,659,969.16 |
1.38% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
95,257 |
$16,085,097.02 |
1.33% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
578,322 |
$15,522,162.48 |
1.29% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
39,012 |
$13,784,500.08 |
1.14% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
236,102 |
$13,500,312.36 |
1.12% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
39,920 |
$10,738,480.00 |
0.89% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
57,745 |
$9,043,444.45 |
0.75% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
320,791 |
$6,826,432.48 |
0.57% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
62,725 |
$6,837,025.00 |
0.57% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
224,868 |
$6,804,505.68 |
0.56% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
161,767 |
$6,579,063.89 |
0.55% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
47,176 |
$6,550,859.36 |
0.54% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
103,214 |
$6,541,703.32 |
0.54% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
60,499 |
$6,325,775.44 |
0.52% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
19,718 |
$6,194,409.70 |
0.51% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
89,737 |
$5,837,391.85 |
0.48% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
219,848 |
$5,621,513.36 |
0.47% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
119,253 |
$5,505,911.01 |
0.46% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
35,247 |
$5,596,871.13 |
0.46% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
685,931 |
$5,604,056.27 |
0.46% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
245,359 |
$5,579,463.66 |
0.46% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
40,313 |
$5,455,961.42 |
0.45% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
37,937 |
$5,155,638.30 |
0.43% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
96,805 |
$4,990,297.75 |
0.41% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
53,078 |
$4,777,020.00 |
0.40% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,604 |
$4,728,948.24 |
0.39% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
84,538 |
$4,364,696.94 |
0.36% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
82,203 |
$3,935,057.61 |
0.33% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
49,443 |
$3,709,461.17 |
0.31% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
68,017 |
$3,349,157.08 |
0.28% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
193,833 |
$3,198,244.50 |
0.27% |
| US Dollar |
$USD |
|
Other |
2,516,087 |
$2,516,086.67 |
0.21% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|